循環器ジャーナル71巻4号

2023年10月発行

特集 変革期を迎えた肺高血圧症—次世代の病態理解，診断，治療とは？ Ⅱ.各論：各種肺高血圧症の診断と治療

肺疾患に合併する肺高血圧症の診断と治療

著者： 内藤亮¹ 田邉信宏² 鈴木拓児³

所属機関： ¹千葉大学医学部附属病院呼吸器内科 ²千葉県済生会習志野病院肺高血圧症センター ³千葉大学大学院医学研究院呼吸器内科学

ページ範囲：P.550 - P.554

POINT
●肺疾患に伴う3群肺高血圧は，肺高血圧の中でも特に予後不良である．
●肺高血圧の重症度だけでなく呼吸機能検査，胸部CTなどを踏まえ治療方針を考慮する．
●海外では吸入トレプロスチニルが良好な成績を示し，国内でも治験が進行中である．

参考文献

1）Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects : a systematic review. Eur Respir J 2009 ; 34 : 888-94.

2）Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019 ; 53 : 1801913.

3）Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 ; 43 : 3618-731.

4）Tanabe N, Taniguchi H, Tsujino I, et al. Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology 2015 ; 20 : 805-12.

5）Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry : Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012 ; 39 : 945-55.

6）Wrobel JP, Thompson BR, Williams TJ. Mechanisms of pulmonary hypertension in chronic obstructive pulmonary disease : a pathophysiologic review. J Heart Lung Transplant 2012 ; 31 : 557-64.

7）Ward JP, Knock GA, Snetkov VA, et al. Protein kinases in vascular smooth muscle tone--role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. Pharmacol Ther 2004 ; 104 : 207-31.

8）Henno P, Boitiaux JF, Douvry B, et al. Tobacco-associated pulmonary vascular dysfunction in smokers : role of the ET-1 pathway. Am J Physiol Lung Cell Mol Physiol 2011 ; 300 : L831-9.

9）Farkas L, Gauldie J, Voelkel NF, et al. Pulmonary hypertension and idiopathic pulmonary fibrosis : a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 2011 ; 45 : 1-15.

10）Andersen KH, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012 ; 31 : 373-80.

11）Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005 ; 172 : 189-94.

12）Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009 ; 3 : 15-21.

13）Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension（RISE-IIP） : a randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019 ; 7 : 780-90.

14）Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019 ; 53 : 1801914.

15）Ghofrani HA, Grimminger F. Soluble guanylate cyclase stimulation : an emerging option in pulmonary hypertension therapy. Eur Respir Rev 2009 ; 18 : 35-41.

16）Tanabe N, Kumamaru H, Tamura Y, et al. Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circ J 2021 ; 85 : 333-42.

17）Olsson KM, Hoeper MM, Pausch C, et al. Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease : results from the COMPERA registry. Eur Respir J 2021 ; 58 : 2101483.

18）McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension : a randomized controlled clinical trial. J Am Coll Cardiol 2010 ; 55 : 1915-22.

19）Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med 2021 ; 384 : 325-34.

20）Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension : a post-hoc analysis of the INCREASE study. Lancet Respir Med 2021 ; 9 : 1266-74.

21）Kolb M, Orfanos SE, Lambers C, et al. The Antifibrotic Effects of Inhaled Treprostinil : An Emerging Option for ILD. Adv Ther 2022 ; 39 : 3881-95.